Compare IHT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | KZIA |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 161.5M |
| IPO Year | N/A | 1999 |
| Metric | IHT | KZIA |
|---|---|---|
| Price | $1.34 | $9.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 31.1K | ★ 2.0M |
| Earning Date | 12-15-2025 | 12-26-2025 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,443,699.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.25 | $2.86 |
| 52 Week High | $4.24 | $21.00 |
| Indicator | IHT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 45.39 |
| Support Level | $1.25 | $9.14 |
| Resistance Level | $1.52 | $12.20 |
| Average True Range (ATR) | 0.09 | 2.42 |
| MACD | 0.01 | -0.49 |
| Stochastic Oscillator | 33.33 | 15.74 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.